Therapix Biosciences Appoints Prof. Ari Shamiss (M.D., M.P.A.) to the Company's Board of Directors

Therapix Biosciences Appoints Prof. Ari Shamiss (M.D., M.P.A.) to the Company's Board of Directors

Israel, May 7, 2020 /PRNewswire/ -- Therapix Biosciences Ltd. (Nasdaq: TRPX) (the "Company"), a specialty, clinical-stage

pharmaceutical company focusing on the development of cannabinoid-based treatments announces today the appointment of Prof. Ari

Shamiss (M.D., M.P.A.) to the Company's Board of Directors.

Prof. Shamiss is the outgoing CEO of Assuta Medical Centers,

the largest private hospital network in Israel, and consists of eight hospitals and medical centers. Prof. Shamiss was the Director

of Sheba General Hospital at Tel Hashomer for 10 years ending in August 2016, and is a co-founder of Assuta Life Ventures (ALiVe),

Prof. Shamiss, is also a board member and advisory at numerous high-tech companies, and is involved in numerous global business

projects in healthcare technology and infrastructure.

an M.D. from the Technion Institute and an M.P.A. from Harvard University. He is certified in internal medicine, hypertension

and healthcare management and he is a Professor of Medicine and Vice Dean at Ben Gurion University School of Medicine.

the Surgeon General for the Israel Air Force (Col. Ret.) and the Director of its Aeromedical Institute. Prof. Shamiss is a graduate

in excellence of the U.S. Navy Aerospace Medical Institute.

to have Prof. Ari Shamiss be part of Therapix," said Ascher Shmulewitz, M.D., Ph.D., Chairman of

Therapix." Prof. Shamiss has a rare set of skills that includes a combination of strong clinical, academic, as well

as, business leadership. We are hopeful that his knowledge and experience in the healthcare system can help bring the company's

unique and leading technology to the market."

Therapix for several years and I look forward to be a part of the organization," said Prof. Shamiss. "Therapix's

technology has the potential to create game-changing therapies in several indications."

Biosciences (Nasdaq: TRPX):

Therapix Biosciences

Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. Our

focus is creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus,

the company is currently engaged in the following drug development programs based on tetrahydrocannabinol (THC) and/or non-psychoactive

cannabidiol (CBD): THX-110 for the treatment of Tourette syndrome and for the treatment of obstructive sleep apnea; THX-160 for

the treatment of pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy. Please visit our website

for more information at www.therapixbio.com, the content of which is not a part of this press release.

release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities

Litigation Reform Act of 1995 and other Federal securities laws. For example, the Company is using forward-looking statements

when it discusses that Prof. Shamiss's knowledge and experience in the healthcare system can help bring the company's unique

and leading technology to the market, and that Therapix's technology has the potential to create game-changing therapies

in several indications. Because such statements deal with future events and are based on the Company's current expectations, they

are subject to various risks and uncertainties and actual results, performance or achievements of the Company could differ materially

from those described in or implied by the statements in this press release. The forward-looking statements contained or implied

in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors"

the Company's Annual Report on Form 20-F filed with the SEC on May 15, 2019, and in subsequent filings with the U.S. Securities

and Exchange Commission. Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise

any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future

events or circumstances or otherwise.